Impaired activation of lesional CD8⁺ T-cells is associated with enhanced expression of Programmed Death-1 in Indian Post Kala-azar Dermal Leishmaniasis

Shibabrata Mukherjee¹, Ritika Sengupta¹, Debanjan Mukhopadhyay¹,⁶, Claudia Braun², Sneha Mitra³, Susmita Roy¹, Nilay Kanti Das¹, Uttara Chatterjee⁴, Esther von Stebut⁵ & Mitali Chatterjee¹

Post Kala-azar dermal leishmaniasis (PKDL), caused by *Leishmania donovani* is the dermal sequel of Visceral Leishmaniasis and importantly, is the proposed disease reservoir. The survival of *Leishmania* parasites within monocytes/macrophages hinges on its ability to effectively nullify immune activation mechanisms. Thus, delineating the disease-promoting immune mechanisms can facilitate development of immunotherapeutic strategies. Accordingly, in the absence of an animal model, this study aimed to delineate the status of CD8⁺ T-cells in patients with PKDL. At disease presentation, the absence of CD4⁺ T-cells at lesional sites was concomitant with an overwhelming infiltration of CD8⁺ T-cells that demonstrated an absence of Perforin, Granzyme and Zap-70, along with an enhanced expression of Programmed Death-1 (PD-1) and the skin-homing CCL17. Additionally, the lesional CCR4⁺ CD8⁺ population was associated with an enhanced expression of IL-10 and IL-5. In circulation, the enhanced CD8⁺ CCR4⁺ T-cell population and raised levels of CCL17/22 was associated with an increased frequency of PD-1, while CD127 was decreased. Taken together, in PKDL, the enhanced plasma and lesional CCL17 accounted for the dermal homing of CD8⁺ CCR4⁺ T-cells, that along with a concomitant upregulation of PD-1 and IL-10 mediated immune inactivation, emphasizing the need for designing immunotherapies capable of reinvigorating T-cell potency.

The Leishmaniases, caused by the protozoan parasite *Leishmania*, comprise a diverse group of neglected tropical diseases having a range of clinical features varying from innocuous self-healing cutaneous lesions to fatal visceralization or a metastatic dermal dissemination. Post Kala-azar Dermal Leishmaniasis (PKDL), usually presents in patients with a history of treated Visceral Leishmaniasis (VL) caused by *L. donovani* and is possibly the most challenging variant of Leishmaniasis, especially in terms of its etiopathogenesis. Patients with PKDL present with papulonodular (polymorphic) or hypomelanotic lesions (macular), and the disease is confined to South Asia and East Africa (mainly Sudan). In South Asia, approximately 5–10% of apparently cured VL patients develop PKDL, as against 50–60% in Sudan. As VL is anthroponotic, PKDL cases are considered as the disease reservoir, emphasizing their inclusion as a component of the ongoing VL elimination programme. In order to achieve this goal of elimination, it is important to delineate the pathophysiology so that informed decisions can be made regarding the most appropriate and cost effective treatment approach. This necessitates an understanding of the...
Intracellular pathogens like *Leishmania* have evolved innovative approaches to evade immune responses that include interference with antigen processing/prentation, altered phagocytosis, induction of immune regulatory pathways and manipulation of costimulatory molecules. Accordingly, the outcome of *Leishmania* infections is influenced by functionally distinct T-cell populations, namely Th1 (IL-2, IFN-γ, IL-6, TNF-α etc.), Th2 (IL-4, IL-13) and Tr1 (IL-10, TGF-β)\(^\text{11}\). Cutaneous Leishmaniasis (CL), is possibly the best documented example of differential activation, wherein disease susceptibility is associated with a predominant Th2 proliferation, while healing responses are associated with an expansion of IFN-γ producing CD4+ Th1 cells, secondary to production of IL-12\(^\text{11}\). In VL, the disease is less defined and is associated with a mixed Th1/Th2 immune profile, along with impairment of macrophage functions\(^\text{12–14}\). Akin to VL, the pathobiology of PKDL involves an enhanced Th1/Th2 response with a Th2 bias, as evident by increased levels of IL-4, IL-5, IL-13, IL-10 and TGF-β, with a preponderance of circulating CD8+IL-10+ T-cells\(^\text{15–19}\).

In PKDL, a disease where no animal model exists, information is derived solely from human studies, and understandably remains limited. Studies have endorsed the presence of a systemic and dermal immunosuppressive milieu and includes the presence of an increased population of antigen-specific IL-10 producing anergic T-cell population in peripheral blood, a decreased presence of dendritic cells at lesional sites, dampening of the CD26 regulated pathways, a huge infiltration of CD68+ alternatively activated macrophages and a dermal pathology dominated by IL-10 and FoxP3\(^\text{5,17,20}\), that individually or more likely collectively contribute towards establishment of a pro-parasitic milieu. In the peripheral blood of polymorphic PKDL as compared to the macular variant, stimulation with *Leishmania* antigen enhanced levels of activated CD8+ and CD4+ T-cells. However, what remains poorly defined in PKDL is the status of chemokines and T-cells at the lesional sites, along with defining their contribution, if any, in supporting disease progression. Accordingly in this study, the activation status of CD4+ and CD8+ T-cells, cytotoxic markers e.g. Perforin, Granzyme and p-Zap-70, inhibitory receptor-Programmed death-1 (PD-1), skin homing chemokine CCL17 and its receptor, Chemokine Receptor 4 (CCR4) along with IL-5 and IL-10 were evaluated in dermal lesions of patients with PKDL. The results demonstrated an increased proportion of CD8+ CCR4+ T-cells and CCL17/CCL22 indicative of dermal homing, while the upregulation of PD-1 and IL-10 suggested impaired activation of CD8+ T-cells. Taken together, this dermal homing of anergic/exhausted CD8+ T-cells supported parasite survival and disease progression in patients with PKDL.

**Results**

The study population included patients with PKDL (n = 20) recruited from 2004–2014, whose median age was 27.50 years with a male preponderance (Table 1)\(^\text{3,25,26}\). *The majority demonstrated hypopigmented, papular and/or nodular lesions, termed ‘polymorphic’ (n = 18, 90.0%), while a minority presented with hypopigmented lesions termed ‘macular’ (n = 2, 10.0%). The papular/nodular lesions appeared primarily on sun-exposed areas like face, neck and upper limbs and ranged from 10–12 in number, whereas for the macular variant, the distribution was more diffuse (Supplementary Fig. S1). All were ITS-1 PCR positive whereas Leishman-Donovan (LD) bodies were detected only in Giemsa stained smears of the polymorphic variant. Two patients gave no prior history of VL, while in the remaining 18, the mean time interval between cure from VL and onset of PKDL was 2.75 years (Table 1). Following completion of treatment, polymorphic PKDL cases showed complete resolution of papules/nodules whereas in macular PKDL, there was substantial reduction in hypopigmentation (Supplementary Fig. S1).*

**Extensive dermal infiltration and absence of granuloma are features of Indian PKDL.** An overall histopathological analysis by H&E staining showed a dense, diffuse inflammatory cell infiltrate involving the entire dermis, consisting mainly of lymphocytes, macrophages and plasma cells, and varied from severe in the polymorphic cases to patchy perivascular and periappendageal with relative sparing of the reticular dermis in the macular variant. Other features included an atrophic epidermis, follicular plugging, hyperkeratosis and papillomatosis. Unlike leprosy, the narrow sub-epidermal Grenz zone was spared and there were no well-formed granuloma. The neural Schwann cells remained unaffected and did not harbour parasites; furthermore, except for one case where perineural infiltration was prominent\(^\text{27}\), none reported any loss of sensation or involvement of the sub-cutis (Supplementary Fig. S2).

**CD8+ T-cells predominated in the dermal infiltrate.** In Indian PKDL Rathi et al.\(^\text{28}\) reported a preponderance of T-suppressor over T-helper cells but as the cellular phenotype had not been characterized, further studies are warranted, especially to establish their activation status. Immunohistochemical analysis at the lesional site showed a conspicuous absence of CD4+ T-cells, *vis-a-vis* healthy controls (0 vs. 30.45 (19.00–45.13),

| Characteristics | Patients with PKDL (n = 20) | Healthy controls (n = 10) |
|-----------------|-----------------------------|---------------------------|
| Age (years)     | 27.50 (18.25–34.35)         | 30.43 (19.56–37.45)       |
| Sex ratio (M:F) | 3:4:1                       | 4:1                       |
| Disease duration (years) | 2.71 (1.00–11.20) | NA                       |
| Interval between cure of VL and onset of PKDL in years | 2.75 (1.00–23.00) | NA                       |

Table 1. Study population. *Values are expressed as median (IQR). M = Male; F = Female; NA = Not applicable; VL = Visceral Leishmaniasis.*
**SCIENTIFIC REPORTS** | (2019) 9:762 | DOI:10.1038/s41598-018-37144-y

---

**Figure 1.** Distribution of T-cells in dermal lesions of patients with PKDL. (a) Representative immunohistochemical profiles of CD4<sup>+</sup> T-cells from dermal biopsies of a healthy control, patient with PKDL and post treatment (10X magnification). (b) Scatter plots of CD4<sup>+</sup> T-cells in dermal biopsies of healthy controls (●, n = 5) patients with PKDL (■, n = 10) and post treatment (▲, n = 10). Each horizontal bar represents the median value. (c,d) Representative immunohistochemical profiles of CD8<sup>+</sup> T-cells from dermal biopsies of a healthy control, patient with PKDL and post treatment (10X and 40X magnification). (e) Scatter plots of CD8<sup>+</sup> T-cells in dermal biopsies of healthy controls (●, n = 5) patients with PKDL (■, n = 9) and post treatment (▲, n = 9). Each horizontal bar represents the median value. (f) Before (●) and after (▲) treatment plots of CD8<sup>+</sup> T-cells.

---

**Figure 1.** Distribution of T-cells in dermal lesions of patients with PKDL. (a) Representative immunohistochemical profiles of CD4<sup>+</sup> T-cells from dermal biopsies of a healthy control, patient with PKDL and post treatment (10X magnification). (b) Scatter plots of CD4<sup>+</sup> T-cells in dermal biopsies of healthy controls (●, n = 5) patients with PKDL (■, n = 10) and post treatment (▲, n = 10). Each horizontal bar represents the median value. (c,d) Representative immunohistochemical profiles of CD8<sup>+</sup> T-cells from dermal biopsies of a healthy control, patient with PKDL and post treatment (10X and 40X magnification). (e) Scatter plots of CD8<sup>+</sup> T-cells in dermal biopsies of healthy controls (●, n = 5) patients with PKDL (■, n = 9) and post treatment (▲, n = 9). Each horizontal bar represents the median value. (f) Before (●) and after (▲) treatment plots of CD8<sup>+</sup> T-cells.

---

**Status of CCL17 and CCL22 in PKDL.** In PKDL, there is an increased presence of alternatively activated CD68<sup>+</sup> macrophages<sup>21,23</sup> that possibly supported an increased presence of T-cell chemokines CCL17/CCL22, accounting for the increased presence of CD8<sup>+</sup> T-cells<sup>29</sup>. Immunohistochemical analysis of the lesional site showed a significantly higher proportion of CCL17<sup>+</sup> cells, mainly histiocytes, *vis-a-vis* their absence in healthy controls, 18.19(15.13–19.58) vs. 0 (Fig. 2a,b). Treatment translated into a significant decrease, being 4.21(2.13–8.24), p < 0.05 (Fig. 2a,b), which was evident even on an individual basis, p < 0.01 (Fig. 2a,b). The circulating levels of CCL17 as measured using a multiplex ELISA based assay were significantly up regulated as compared to healthy controls, 161.60(137.40–173.20) vs. 43.20(26.36–64.50) pg/ml, p < 0.001 (Fig. 2c). Similarly, levels of CCL22 were also significantly raised, 665.90(614.40–819.20) vs. 321.10(195.30–423.10) pg/ml, p < 0.001, and declined significantly with treatment to 323.20(181.40–544.00) pg/ml, p < 0.01 (Fig. 2c). However, in one case post treatment, levels of CCL17 increased and in three cases remained unchanged. With regard to CCL22, levels were increased post treatment in two patients. Overall on a paired basis, both these chemokines demonstrated a significant decrease (Fig. 2c).

**Increased CD8<sup>+</sup>CCR4<sup>+</sup> cells in dermal lesions and peripheral blood.** The raised levels of dermal homing chemokines CCL17 and CCL22 (Fig. 2a–c) suggested that the increased presence of CD8<sup>+</sup> T-cells was secondary to their homing to dermal lesions.<sup>30</sup> Accordingly, the status of CCR4, the chemokine receptor for CCL17/22 was examined at dermal sites by immunohistochemistry and flow cytometry in peripheral blood. In dermal lesions, the proportion of CCR4<sup>+</sup> cells was significantly up regulated, 69.56(67.09–72.78) vs. 3.26(2.11–3.88), p < 0.001 (Fig. 3a) and declined significantly with treatment, 21.23(19.96–22.35), p < 0.05, and was
confirmed on an individual basis, \( p < 0.01 \) (Fig. 3a). Dual staining confirmed the localization of CCR4 on CD8\(^+\) T-cells (Fig. 3b), which decreased with treatment, 65.85(43.56–73.65) vs. 20.20(8.52–15.13), \( p < 0.01 \) (Fig. 3b). Furthermore, the raised plasma levels of CCL17 and 22 correlated positively with the proportion of dermal CD8\(^+\)/CCR4\(^+\)T-cells, \( r = 0.53 \) and \( r = 0.48 \) respectively (Fig. 3b). In peripheral blood, the frequency of CCR4\(^+\) within the CD8\(^+\) population was significantly higher than healthy controls, 81.98(64.71–34.23) vs. 49.87(39.85–58.36)\%, \( p < 0.01 \) (Fig. 3c) whereas the frequency of CXCR3\(^+\) within the CD8\(^+\) population remained unaltered, and was comparable with healthy controls, 27.20 (25.90–31.25) vs. 27.10 (23.85–30.80)\% (Supplementary Fig. S4).

Decreased expression of granzyme and perforin in lesional CD8\(^+\) T-cells. To assess the cytotoxic potential of lesional CD8\(^+\) T-cells, the lesional status of Perforin-H and Granzyme-B along with nuclear factor Zap70 was examined by immunohistochemistry\(^{31}\). Despite an overwhelming presence of CD8\(^+\) T-cells, PKDL cases demonstrated a conspicuous absence of Perforin, Granzyme and Zap70 in the dermal lesions (Fig. 4a–c). In peripheral blood, the activation status of CD8\(^+\) T-cells was examined by flow cytometry in terms of activation markers, CD127 and CD69\(^{32,33}\) along with Perforin and Granzyme. During active disease, the frequency of CD127\(^+\) within the CD8\(^+\) population was significantly higher than healthy controls, 81.98(64.71–34.23) vs. 49.87(39.85–58.36)\%, \( p < 0.01 \) (Fig. 4d,e) whereas the frequency of CXCR3\(^+\) within the CD8\(^+\) population remained unaltered, and was comparable with healthy controls, 27.20 (25.90–31.25) vs. 27.10 (23.85–30.80)\% (Supplementary Fig. S4).

Enhanced presence of markers of exhaustion in lesional and circulatory CD8\(^+\) T-cells. The absence of cytotoxic markers Perforin, Granzyme, Zap-70 in dermal lesions suggested exhaustion of CD8\(^+\) T-cells and accordingly, the presence of Programme Death 1 (PD-1), a marker of exhaustion was examined\(^{34,35}\). In dermal lesions, the mRNA expression of PD-1 was elevated, 42.86(28.42–58.28) vs. 0 (Fig. 5a), and regressed...
significantly with treatment, 12.35(10.93–13.49), p < 0.01 (Fig. 5a). This was corroborated on an individual basis, p < 0.001 (Fig. 5a). Furthermore, a significant increase in PD-1 expression was also demonstrated by immunohistochemistry in dermal lesions, absent in healthy individuals, 18.50(17.94–20.03) vs. 0 (Fig. 5b); treatment translated into a significant decrease, 3.14(0–5.68), p < 0.01 (Fig. 5b). The scenario was mirrored in peripheral blood as PKDL cases demonstrated a significantly elevated frequency of PD-1 within CD8+ T-cells, 38.03(35.75–39.84) vs. 21.03(20.45–22.84) %, p < 0.01 (Fig. 5c,d), which decreased with treatment, 24.88(20.37–28.00) %, p < 0.01 (Fig. 5c,d), and this trend was evident even on an individual basis, p < 0.01 (Fig. 5e).

As exhaustion is associated with an immunosuppressive milieu comprising IL-4 and IL-10 35, their plasma levels in PKDL were examined and found to be significantly raised, and with treatment a significant decrease was reported 16. Furthermore, as the sustenance of CCR4+ T-cells (Fig. 3) is generally supported by an IL-10 and IL-5 rich milieu 36,37, their expression was examined at lesional sites. During active disease, there was a strongly positive diffuse sub-epidermal expression of IL-10 which receded with treatment (n = 10, Fig. 6a). Concomitantly, an enhanced expression of IL-5 was evident, 18.12(41.35–60.14) vs. 0 (Fig. 6b,c), which also declined with treatment, 4.30(10.21–31.25), p < 0.05 (Fig. 6b,c); this was mirrored on an individual basis, p < 0.01 (Fig. 6c). As the expression of IL-10 at the lesional sites was diffuse, individual cells could not be counted and hence, a correlation, if any, between PD-1 and IL-10 was not assessed.

**Discussion**

CD8+ naive T-cells, being mediators of pathogen control, are targets for microbial modification. To achieve this, they orchestrate differentiation via induction of cytotoxic/effecter cells that in turn release IFN-γ, activate macrophages and dendritic cells, as also promote differentiation of CD4+ T-cells 38. In dermal Leishmaniais, CD8+ T-cells show a diverse disease repertoire with varying intensities of inflammatory infiltrate, and depending on the parasite species, can be protective or deleterious 39. In patients with localised self healing CL (LCL) caused by L. major, an increased proportion of CXCR3/CD4+ and/or CD8+ T-cells provided a protective role 40, whereas, in severe forms of CL caused by L. braziliensis, increased disease severity occurred secondary to dysregulated CD8+ T-cells.
Studies have shown skin-resident, IFN-γ producing CD4+ T-cells protect against L. major, via recruitment and activation of inflammatory monocytes that mediate parasite elimination by production of reactive oxygen species and nitric oxide42. Conversely, in patients with diffuse CL (DCL) caused by L. mexicana, the uncontrolled spread of the parasite was associated with an enhanced presence of exhausted CD8+ T-cells43. In a head on comparison of LCL vs. DCL, it was demonstrated that CD8+ T-cells sourced from DCL showed a significant reduction in their effector responses vis-à-vis their self healing variant43. In self healing PKDL in East Africa/Sudan, a preponderance of CD4+ T-cells vis-a-vis its CD8+ variant was demonstrated44. In contrast, in Indian non self-healing PKDL, although there was a massive influx of CD3+ T-cells20, it comprised primarily of CD8+, with a near total absence of CD4+ T-cells (Fig. 1) that possibly facilitated development of a pro-parasitic milieu and disease sustenance. This absence of CD4+ T-cells can be attributed to the enhanced presence of alternatively activated macrophages, that via IL-4/IL-13 mediated activation of Stat-6 inhibit T-cell proliferation and survival45–47.

In Leishmaniasis, the inhibition of IL-12 along with an induction of IL-10 and TGFβ underlies the bias towards a Th2 response45. In PKDL, the enhanced secretion of IL-10 and TGF-β by antigen-stimulated PBMCs has been associated with disease severity15. Cellular infiltration is common to Sudanese and South Asian PKDL (Supplementary Fig. S2), but the absence of granuloma in the latter can be attributed to the IL-10 rich milieu (Fig. 6), which can inhibit granuloma formation as demonstrated in tuberculosis48. Furthermore, the resultant microenvironment of IL-4/IL-13 and IL-10 facilitated the emergence of alternatively activated M2 monocytes/macrophages23, that in turn supported the expression of Th2 chemoattractants, CCL17 and CCL22 (Fig. 2). These chemokines upon interaction with their receptor CCR4, facilitate migration of skin homing T-cells to the pathologic site, and was endorsed in PKDL by the increased presence of IL-5 and IL-10 (Fig. 6)37. Post treatment in a few cases, the levels of CCL17 and CCL22 remained increased or unchanged, that may be attributed to their longer duration of disease (6–12 years) vis-a-vis the median disease duration of 2.71 years. The enhanced frequency of CD8+CCR4+ T-cells in circulation and dermal lesions promoted the dermal extravasation of CD8+ T-cells (Fig. 3).

Figure 4. Activation status of lesional and peripheral CD8+ T-cells in patients with PKDL. (a–c) Representative immunohistochemical profiles of Perforin (a), Granzyme (b) and Zap70 (c) in dermal biopsies of a healthy control, patient with PKDL (10X magnification); a reactive lymph node served as the positive control (40X magnification). (d) Representative quadrant plots indicating frequency (%) of CD127+ within CD8+ T-cells in peripheral blood of a healthy control, patient with PKDL and post treatment. (e) Scatter plots showing frequency (%) of CD127+ within CD8+ T-cells of healthy controls (●, n = 9), patients with PKDL (■, n = 10) and post treatment (▲, n = 9). The proportion of CD127+ within the entire CD8+ population was calculated by dividing the percentages of upper right quadrant by the sum of upper and lower right quadrant. Each horizontal bar represents the median value. Before (●) and after (○) treatment plots of CD127+ in CD8+ T-cells in patients with PKDL.
Figure 5. Presence of Programmed Death-1 (PD-1) in dermal lesions and circulation of patients with PKDL. (a) Representative mRNA expression profiles of PD-1 (cropped from original gel images, full-length gels are presented in Supplementary Fig. S6) in dermal biopsies of healthy controls (N1–3), patients with PKDL (Pre1–3) and post treatment (Post1–3). Scatter plots of PD-1 in healthy controls (●, n = 5), at disease presentation (■, n = 10) and post treatment (▲, n = 10). Each horizontal bar represents the median value. Before (●) and after (○) treatment plots of PD-1. (b) Representative immunohistochemical profiles of PD-1+ cells from dermal biopsies of a healthy control, patient with PKDL and post treatment (10X and 40X magnification). Scatter plots of PD-1+ cells in dermal biopsies of healthy controls (●, n = 5) patients with PKDL (■, n = 9) and post treatment (▲, n = 9). Each horizontal bar represents the median value. Before (●) and after treatment (○) plots of PD-1+ cells. (c) Representative quadrant plots indicating the frequency (%) of PD-1+ within CD8+ T-cells in peripheral blood of a healthy control, patient with PKDL and post treatment. (d) Scatter plots of PD-1+ in CD8+ T-cells of healthy controls (●, n = 10), at disease presentation (■, n = 10) and post treatment (▲, n = 10). Each horizontal bar represents the median value. The proportion of PD-1+ in the entire CD8+ population was calculated by dividing percentages of the upper right quadrant by the sum of upper and lower right quadrant. (e) Before (●) and after treatment (○) plots of PD-1+ in CD8+ T-cells.
In CL, the higher expression of CXCR3 vis-a-vis CCR4 accounted for their self healing propensity. This was corroborated in CL caused by *L. braziliensis*, wherein during the early phase of the disease, there is a raised expression of CXCR3. However, in peripheral blood and dermal lesions of PKDL cases, the frequency of CXCR3+ remained unaltered as compared to healthy individuals (Supplementary Fig. S4). Subsequently, in the late stage of the disease, a higher expression of CCL17 and CCR4 has been reported, suggestive of a preferential recruitment of regulatory T-cells that facilitated disease progression.

A blockade of costimulation can result in the induction of T helper cell anergy and subsequent differentiation of antigen-specific CD8+ T suppressor/regulatory cells. Accordingly, it may be envisaged that in PKDL, the enhanced frequency of IL-10 producing antigen-specific circulating CD8+ T-cells and CD8+CD28− T-cells, along with impairment of antigen specific proliferative responses caused attenuation of the effector CD8+ T-cell responses in the dermal lesions, as evident by the conspicuous absence of Perforin and/or Granzyme positivity (Fig. 4) and absence of tissue damage. This was corroborated by absence of the intracellular signaling molecule, IL-5, as shown in Figure 6.

Figure 6. Distribution of IL-10 and IL-5 in dermal lesions of patients with PKDL. (a) Representative immunohistochemical profiles of IL-10 from dermal biopsies of a healthy control, a patient with PKDL and post treatment (40X magnification). (b) Representative immunohistochemical profiles of IL-5 from dermal biopsies of a healthy control, a patient with PKDL and post treatment (10X and 40X magnification). (c) Scatter plots showing distribution of IL-5+ cells in healthy controls (●, *n* = 5), at disease presentation (■, *n* = 10) and post treatment (▲, *n* = 10). Each horizontal bar represents the median value. Before (●) and after (○) treatment plots of IL-5+ cells.
transcriptase-PCR kit (Qiagen, Hilden, Germany) using gene-specific primers (10 Technologies, USA). Reverse transcriptase-PCR was performed on RNA (50 ng) with the one-step reverse at

Data was acquired in a Luminex 200 Labmap system (Luminex, Austin, TX, USA) and analysed using Bio-Plex (diluted 1:4), using a multiplex detection kit (BioRad, Hercules, CA, USA) as per the manufacturer’s protocol.

parasites have deviously evolved immune escape mechanisms emphasizing the importance of designing immu-
notherapeutic strategies aimed at restoring effector responses.

Materials and Methods
Reagents. Materials were from Sigma Aldrich (St. Louis, Mo, USA) except rK39 immunochromatographic test strips (InBios International, Seattle, WA, USA), anti-human CD4 (clone 4B12, Novoceastra, Newcastle upon Tyne, UK,), Chemokine Receptor 4 (CCR4, clone 1G1), CCR3 Peridinin chlorophyll (PerCP, clone SK7), CCR5 Alexa Fluor 488 (clone RPA-T8), CCR6 PerCP (clone SK1), CCR4 Phycoerythrin (PE, clone 1G1, BD Biosciences, San Jose, CA, USA), PD-1(clone EH1.2.H7) and CD127 (clone A019D5) APC (Biolegend, San Diego, CA, USA), IL-5 (clone 9906, R&D Systems, Minneapolis, MN, USA), CCL17 (clone N-20), IL-10 (clone E-10), PD-1 (clone C-20), Perforin H (clone H-315), Granzyme B (clone 2C5, Santa Cruz Biotechnology, Dallas, TX, USA), antibody diluent, Target Retrieval Solution Citrate pH 6 (S2369), secondary detection system EnVision™ G|2 System/ AP-Rabbit/Mouse (Permanent Red), EnVision™ FLEX Target Retrieval Solution, EnVision™ DuoFLEX Doublestain System (Dako, Glostrup, Denmark), RNALater and RNaseous kit (Ambion, Austin, TX, USA), One-step reverse transcription kit from Qiagen (Hilden, Germany) and Bio-Plex Pro™ Human Chemokine Panel 40-Plex (BioRad, Hercules, CA, USA).

Study population. Patients clinically diagnosed as PKDL (n = 20) were recruited from the Dermatology outpatient department, School of Tropical Medicine, Kolkata, India. The initial diagnosis was based on clinical features, a prior history of VL, rK-39 positivity, or if resident in an area endemic for VL. Diagnosis was confirmed by ITS-1 PCR and/or Giemsa staining in dermal biopsies. Patients were randomly allocated to receive SAG (20 mg/kg bw/day i.m., 4 months, n = 8) or Miltefosine (100 mg/day p.o., 4 months, n = 12). Age and gender-matched healthy volunteers (n = 10) were recruited from non-endemic and endemic areas and were negative for anti-leishmanial antibodies and ITS-1 PCR. A dermal biopsy (4 mm) was obtained using a punching biopsy by anaesthetizing the area with lignocaine and venous heparinised blood (5 ml) was collected at disease presentation and completion of treatment. Due to limited availability of biological material, all markers were not evaluated in every patient, and were randomly selected ensuring that at least 5 individuals were studied per assay.

Immunohistochemistry. For single staining, formalin-fixed paraffin embedded sections (1 µm), were deparaffinised by xylene and rehydrated using alcohol (100–70%) and distilled water. After heat-induced epitone retrieval at pH 6, the slides were incubated for 1 h with the primary antibody (1:40 for CD4, 1:50 for CD8, CCR4, PD-1, IL-10, IL-5, CCL-17, Granzyme B, Perforin H, Zap-70), washed with Tris buffered saline containing 0.05% Tween-20 (pH 7.4) and incubated with EnVision™ G2 System/AP-Rabbit/Mouse (Permanent Red) as per the manufacturer’s protocol and counter stained with hematoxylin. Sections from human lymph nodes served as positive controls and for healthy controls, 4 mm skin biopsies were obtained from laboratory volunteers or the foreskin of individuals undergoing voluntary circumcision. For dual staining, sections were deparaffinised and dual staining performed using EnVision™ DuoFLEX Doublestain System. Five fields were manually counted under the light microscope (Axioscope A1, Carl Zeiss, Germany) at 400X magnification and expressed as cells mm-2. To minimize bias, two blinded investigators independently evaluated the slides.

Quantification of circulatory CCL17 and CCL22. Plasma levels of CCL17 and CCL22 were measured (diluted 1:4), using a multiplex detection kit (BioRad, Hercules, CA, USA) as per the manufacturer’s protocol. Data was acquired in a Luminex 200 Labmap system (Luminex, Austin, TX, USA) and analysed using Bio-Plex Manager software version 6.2.

Isolation of total RNA and Reverse transcriptase-PCR analysis. Skin biopsies were stored in RNALater at – 80 °C and total RNA isolated as per the manufacturer’s instructions (Ambion, Life Technologies, USA). Reverse transcriptase-PCR was performed on RNA (50 ng) with the one-step reverse transcriptase-PCR kit (Qiagen, Hilden, Germany) using gene-specific primers (10 µM) for β-actin (F, 5′-CCCAAGGCCAACCGGAGAAGGTAT-3′; R, 5′-GTCCCCGCGACCAGGTCCAG-3′), and PD-1 (F, 5′-ATGTAGCCCGCCCCACACAGA-3′; R, 5′-CATCACTTTTTTCAGGCAT-3′). After incubation at 50 °C for
30 min. and PCR activation (95 °C, 15 min.), the amplification comprised 35 cycles of denaturing (94 °C, 30 seconds), annealing (30 seconds), extension (72 °C, 60 seconds), and a final extension (72 °C, 10 min.) in a thermal cycler (Applied Biosystems, California, USA). Products were resolved on agarose gels (2%) containing ethidium bromide (0.5 μg/ml) and analyzed (G-BOX gel doc, Syngene, Cambridge, UK) using Gene Tools (Version 4.01.04) software, values being normalized to their respective β-actin.

**Immunophenotyping.** Whole blood (100 μl) was surface stained with fluochrome conjugated antibodies to CD69-PE, CD8-PerCP, CCR4-PE, CXCR3-APC, PD1-APC and CD127-APC along with isotype controls and acquired on a FACS Calibur (BD Biosciences, San Jose, CA, USA).

**Intracellular detection of perforin and granzyme.** Blood (100 μl) was incubated with anti-human CD8-PerCP (20 min., room temperature) followed by a 10 min. incubation with Lyse-fix solution (BD Biosciences, San Jose, CA, USA). After a wash with phosphate-buffered saline (PBS, 0.02 M)-2% fetal bovine serum (FBS) and permeabilization in Cytofix-Cytoperm buffer (BD Biosciences, San Jose, CA, USA, 100 μl, room temperature, 20 min.), antihuman PE-conjugated Perforin and Granzyme along with respective isotypes were added. Following a 15 min. incubation in perm-wash buffer, cells were washed and acquired on a flow cytometer.

**Flow cytometry.** Lymphocytes were gated on their characteristic forward vs. side scatter followed by fluorescence; 5000 lymphocytes were acquired and analyzed using CellQuest Pro software (BD Biosciences, San Jose, CA, USA). Fluorescence was evaluated in terms of frequency (% positivity) and expression (geometric mean fluorescence channel, GMFC) in the FL-1 channel for FITC and Alexa 488, for PE in the FL-2 channel, for PerCP in the FL-3 channel and for APC in the FL-4 channel. The lymphocytes were first gated based on their side and forward scatter, the CD8 population was then identified using CD8-PerCP and the frequency of CD127-APC, CD69-PE, Perforin-PE, Granzyme-PE, CCR4-PE, CXCR3-APC and PD1-APC examined within the CD8+ T-cells. Frequency was calculated in the entire CD8+ population by dividing the percentages of upper right quadrant by the sum of upper and lower right quadrant. Analysis was done for fluorescence by Cell-Quest pro software (BD Biosciences, San Jose, CA, USA).

**Statistical analysis.** Results were expressed as median (Interquartile range, IQR) and data analyzed between groups by Kruskal-Wallis Post Dunn test for non-parametric data, while paired data were analyzed using Student’s t-test (for parametric data). Correlation was done using Pearsons correlation for parametric data using GraphPad Prism software (version 5.0, GraphPad software Inc., La Jolla, CA, USA), p < 0.05 being significant.

**Ethics statement.** The study received approval from the Institutional Ethics Committee of School of Tropical Medicine, Kolkata (Order No: 1096 dated: 23.05.2009) and Institute of Post Graduate Medical Education and Research, Kolkata (Ref No. Inst/IEC/1893 dated: 06.08.2005) and all experiments were performed in accordance with relevant guidelines and regulations. Individuals or their legally acceptable representative (if <18 years)
gave a written informed consent. Informed consent was also obtained to publish after maintaining patient confidentiality information/images in an online open-access publication.

Data Availability
All data generated or analysed during this study are included in this article and its Supplementary Information.

References
1. Ganguly, S., Das, N. K., Barbhuiya, J. N. & Chatterjee, M. Post-kala-azar dermal leishmaniasis—an overview. *Int J Dermatol* **49**, 921–931 (2010).
2. Ziljstra, E. E., Musa, A. M., Khalil, E. A., el-Hassan, I. M. & el-Hassan, A. M. Post kala-azar dermal leishmaniasis. *Lancet Infect Dis* **3**, 87–98 (2003).
3. Ramesh, V., Kaushal, H., Mishra, A. K., Singh, R. & Salotra, P. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study. *BMC Public Health* **15**, 1092 (2015).
4. Ziljstra, E. E., Khalil, E. A., Kager, P. A. & el-Hassan, A. M. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. *Br J Dermatol* **143**, 136–143 (2000).
5. Bhattacharya, S. K. & Dash, A. P. Elimination of Kala-Azar from the Southeast Asia Region. *Am J Trop Med Hyg* **96**, 802–804 (2017).
6. Singh, O. P., Hasker, E., Boelaert, M. & Sundar, S. Elimination of visceral leishmaniasis on the Indian subcontinent. *Lancet Infect Dis* **16**, 304–309 (2017).
7. Ziljstra, E. E., Alves, F., Rijal, S., Arana, B. & Alvar, J. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme. *Plos Negl Trop Dis* **11**, e0005877 (2017).
8. Mukhopadhyay, D., Dalton, J. E., Kaye, P. M. & Chatterjee, M. Post kala-azar dermal leishmaniasis: an unresolved mystery. *Trends Parasitol* **30**, 65–74 (2014).
9. Hartley, M. A., Drexler, S., Ronet, C., Beverley, S. M. & Fasel, N. The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. *Trends Parasitol* **30**, 412–422 (2014).
10. Walker, D. M. et al. Mechanisms of cellular invasion by intracellular parasites. *Cell Mol Life Sci* **71**, 1245–1263 (2014).
11. Kaye, P. & Scott, P. Leishmaniasis: complexity at the host-pathogen interface. *Nat Rev Microbiol* **9**, 604–615 (2011).
12. Kumar, R. & Nylen, S. Immunobiology of visceral leishmaniasis. *Front Immunol* **3**, 251 (2012).
13. Roy, S. et al. A defective oxidative burst and impaired antigen presentation are hallmarks of human Visceral Leishmaniasis. *J Clin Immunol* **35**, 56–67 (2015).
14. Kemp, M. et al. *Leishmania donovani*-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. *Infect Immun* **61**, 1069–1073 (1993).
15. Ganguly, S. et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. *J Infect Dis* **197**, 1762–1771 (2008).
16. Mukhopadhyay, D. et al. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. *J Infect Dis* **204**, 1427–1436 (2011).
17. Kataria, G. K., Ansari, N. A., Verma, S., Ramesh, V. & Salotra, P. Fopx3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala-azar dermal leishmaniasis (PKDL) patients. *Plos Negl Trop Dis* **5**, e1171 (2011).
18. Saha, S. et al. IL-10 and TGF-beta mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of *Leishmania donovani* infection in India. *J Immunol* **8**, 5592–5603 (2007).
19. Ansari, N. A., Ramesh, V. & Salotra, P. Interferon (IFN)-gamma, tumor necrosis factor-alpha, interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala-azar dermal leishmaniasis. *J Infect Dis* **194**, 958–965 (2006).
20. Ganguly, S. et al. Enhanced lesional Fopx3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis. *J Invest Dermatol* **130**, 1013–1022 (2010).
21. Mukherjee, S. et al. Decreased presence of Langerhans cells is a critical determinant for Indian Post kala-azar dermal leishmaniasis. *Exp Dermatol* **24**, 232–234 (2015).
22. Mukherjee, S. et al. Decreased presence and secretion of CD26 promotes disease progression in Indian Post kala-azar dermal leishmaniasis. *J Clin Immunol* **36**, 85–94 (2016).
23. Mukhopadhyay, D. et al. M2 Polarization of Monocytes-Macrophages Is a Hallmark of Indian Kala-Azar Dermal Leishmaniasis. *Plos Negl Trop Dis* **9**, e0004145 (2015).
24. Kauriala, H. et al. Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India. *Clin Exp Immunol* **185**, 50–60 (2016).
25. Moulik, S. et al. Monitoring of parasite kinetics in Indian Post Kala Azar Dermal Leishmaniasis. *Clin Infect Dis* **66**, 404–410 (2018).
26. Mukhopadhyay, D. et al. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone. *Int J Dermatol* **55**, 250–255 (2016).
27. DasGupta, S., Mukherjee, S., Das, R. N., Chatterjee, U. & Chatterjee, M. Perineurial infiltration: Not always leprosy. *Ann Trop Med Public Health* **7**, 195–196 (2014).
28. Rath, S. K., Pandhi, R. K., Chopra, P. & Khanna, N. Lesional T-cell subset in post-kala-azar dermal leishmaniasis. *J Clin Immunol* **44**, 12–13 (2005).
29. Campbell, J. J. et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. *Nature* **6746**, 776–780 (1999).
30. Griffith, J. W., Sokol, C. L. & Luster, A. D. Chemokines and chemokine receptors: positioning cells for host defence and immunity. *Ann Rev Immunol* **36**, 659–702 (2014).
31. Wang, H. et al. ZAP-70: an essential kinase in T-cell signaling. *Cold Spring Harb Perspect Biol* **2**, a002279 (2010).
32. Kasch, S. M. et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. *Nat Immunol* **4**, 1191–1198 (2003).
33. Gubser, P. M. et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. *Nat Immunol* **14**, 1064–1072 (2013).
34. Dayakar, A., Chandrasekar, S., Veronika, J., Bhardwaja, V. & Maurya, R. Leptin regulates Granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB/c Mice. *Sci Rep* **7**, 14664 (2017).
35. Carter, L. et al. PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. *Eur J Immunol* **32**, 634–643 (2002).
36. Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. *Immunity* **27**, 670–684 (2007).
37. Jakiela, B. et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. *Rheumatol (Oxford)* **51**, 1887–1893 (2012).
38. Zhang, N. & Bevan, M. J. CD8+ T cells: foot soldiers of the immune system. *Immunology* **2**, 161–166 (2011).
39. Novais, F. O. & Scott, P. CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly. *Semin Immunopathol* **37**, 251–259 (2015).
40. Geiger, B., Wenzel, J. & Hantschke, M. Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCRR3-positive T helper 1/T cytotoxic type 1 cells. *Br J Dermatol* **162**, 870–874 (2010).
Acknowledgements
The work received financial assistance from Indian Council for Medical Research (ICMR) [Grant number: 6/9-7(151)/2017-ECII], Department of Health Research (DHR), Govt. of India [Grant number: DHR/HRD/Fellowship/SUG-05/2015-16] and an ICMR-BMBF exchange programme, INDO/FRC/66/10-1HD, Fund for Improvement of S&T infrastructure in Universities and Higher Educational Institutions (FIST) Program, Dept. of Science & Technology, Govt. of India (DST-FIST) [Grant number: SR/FST/LSI-663/2016] and Dept. of Science & Technology, Govt. of West Bengal [Grant number: Grant number: 969 (Sanc.)/ST/P&ST/9G-22/2016]. SM and S Mitra are recipients of a Senior Research Fellowship from INSPIRE Programme DST; DM and SR are recipients of a Senior Research Fellowship from ICMR and CSIR, Govt. of India respectively, and RS is a recipient of a Junior Research Fellowship from ICMR, Govt. of India.

Author Contributions
S.M., E.S., U.C. and M.C. designed the experiments. S.M., R.S., D.M., C.B., SMitra, S.R., N.D. and U.C. performed the experiments. M.C. supervised the whole work, S.M., M.C. and R.S. wrote the manuscript and all authors reviewed the results and approved the final version of the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-37144-y.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019